EUCTR2007-000597-22-IT进行中（未招募）不适用
The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+ chronic myeloid leucemia (CML) in early chronic phase: a Phase II exploratory, multicenter study - GIMEMA CML0307
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO0 个研究点开始时间: 2007年5月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with a cytologic and cytogenetic confirmed diagnosis of Ph+ CML. 2. Age = 18 years old 3. Early CP (within 6 months from diagnosis) 4. No prior treatment with any antileukemic drugs with the exception of Hydroxyurea (HU) and Anagrelide. 5. WHO performance status of = 2 6. Normal serum level of potassium, total calcium corrected for serum albumin, magnesium and phosporus, or correctable with supplements 7. ALT and AST = 2.5 x ULN or = 5.0 x ULN if considered due to leukaemia. 8. Alkaline phosphatase = 2.5 x ULN unless considered due to leukemia. 9. Serum bilirubin = 1.5 x ULN 10. Serum creatinine = 1.5 x ULN 11. Serum amylase = 1.5 x ULN and serum lipase = 1.5 x ULN. 12. Written informed consent prior to any study procedures being performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •1. Impaired cardiac function, including LVEF < 45% as determined by MUGA scan or echocardiogram, uncontrolled congestive heart failure, uncontrolled hypertension 2. History of myocardial infarction within three months, or uncontrolled angina pectoris. 3. Significant electric heart abnormalities, including history or presence of significant ventricular or atrial tachyarrhythmias, congenital long QT syndrome and/or QTc > 450 msec on screening ECG (using the QTcF formula) . Patients with ventricular pacemakers and clinically significant bradycardias. Patients with heart blocks. 4. History of acute or chronic pancreatitis. 5. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of nilotinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) 6. Use of therapeutic coumarin derivates (i.e. warfarin, acenocoumarol, phenprocoumon). 7. Acute or chronic liver or renal disease considered unrelated to leukaemia 8. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol 9. Patients who are currently receiving treatment with any of the medications listed in Appendix E and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix E have the potential to prolong QT, with the exception of HU and Anagrelide. 10. Patients who have received any antileukemic agents and treatments, including HSCT, with the exception of HU and Anagrelide. 11. Patients who have received any investigational drug = 4 weeks. 12. Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy. 13. Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of nilotinib). Post menopausal women must be amenorrhoic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug. 14. Treatment with any hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF) ?1 week prior to starting study drug. 15. Patients who have received immunotherapy ?1 week prior to starting study drug or who have not recovered from side effects of such therapy. 16. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory). 17. Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention. 18. Patients unwilling or unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
1 期
A muulticenter study to evaluate drug response for the treatment of a white blood cell cancer in early chronic phaseEUCTR2011-002787-25-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO120
招募中
不适用
Therapeutic Targeting of Lyn Kinase with Nilotinib to Treat Chorea-Acanthocytosis - an observational, non-interventional studyG23.9Degenerative disease of basal ganglia, unspecifiedDRKS00024187Sektion für Translationale Neurodegeneration Albrecht KosselKlinik und Poliklinik für NeurologieUniversitätsmedizin Rostock10
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
未知
不适用
Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertensiopulmonary arterial hypertensionJPRN-UMIN000001578Medical Education Center10
已完成
不适用
Discontinuation of tyrosine kinase inhibitor treatment in patients who have obtained complete molecular response after treatment with tyrosine kinase inhibitors for chronic myeloid leukemiaChronic myeloid leukemiaJPRN-UMIN000004798Keio University School of Medicine, Division of Hematology70